Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $13.39 million. The enterprise value is $104.27 million.
Important Dates
The next estimated earnings date is Thursday, April 3, 2025, before market open.
| Earnings Date | Apr 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 17.43 million shares outstanding. The number of shares has increased by 19.01% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 17.43M |
| Shares Change (YoY) | +19.01% |
| Shares Change (QoQ) | +9.74% |
| Owned by Insiders (%) | 3.19% |
| Owned by Institutions (%) | 4.99% |
| Float | 15.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| Forward PS | 0.20 |
| PB Ratio | -0.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.64
| Current Ratio | 1.64 |
| Quick Ratio | 0.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.39 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.19% |
| Return on Invested Capital (ROIC) | -11.28% |
| Return on Capital Employed (ROCE) | -15.20% |
| Revenue Per Employee | $155,595 |
| Profits Per Employee | -$53,511 |
| Employee Count | 380 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.78 |
Taxes
| Income Tax | -102,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.22% in the last 52 weeks. The beta is 1.03, so Trinity Biotech's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -70.22% |
| 50-Day Moving Average | 0.86 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 43.41 |
| Average Volume (20 Days) | 6,342,241 |
Short Selling Information
| Short Interest | 596,795 |
| Short Previous Month | 58,424 |
| Short % of Shares Out | 2.72% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $59.13 million and -$20.33 million in losses. Loss per share was -$2.29.
| Revenue | 59.13M |
| Gross Profit | 21.13M |
| Operating Income | -10.55M |
| Pretax Income | -21.51M |
| Net Income | -20.33M |
| EBITDA | -8.65M |
| EBIT | -10.55M |
| Loss Per Share | -$2.29 |
Full Income StatementBalance Sheet
The company has $2.84 million in cash and $93.72 million in debt, giving a net cash position of -$90.88 million or -$5.21 per share.
| Cash & Cash Equivalents | 2.84M |
| Total Debt | 93.72M |
| Net Cash | -90.88M |
| Net Cash Per Share | -$5.21 |
| Equity (Book Value) | -26.34M |
| Book Value Per Share | -2.54 |
| Working Capital | 18.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.30 million and capital expenditures -$498,000, giving a free cash flow of -$7.80 million.
| Operating Cash Flow | -7.30M |
| Capital Expenditures | -498,000 |
| Free Cash Flow | -7.80M |
| FCF Per Share | -$0.45 |
Full Cash Flow StatementMargins
Gross margin is 35.74%, with operating and profit margins of -17.84% and -34.39%.
| Gross Margin | 35.74% |
| Operating Margin | -17.84% |
| Pretax Margin | -34.56% |
| Profit Margin | -34.39% |
| EBITDA Margin | -14.63% |
| EBIT Margin | -17.84% |
| FCF Margin | n/a |